Cargando…

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis

BACKGROUND: Surrogate endpoints (SEs), such as progression-free survival (PFS) and objective response rate (ORR), are frequently used in clinical trials. The relationship between SEs and overall survival (OS) has not been well described in metastatic urothelial cancer (MUC). OBJECTIVE: We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghali, Fady, Zhao, Yibai, Patel, Devin, Jewell, Teresa, Yu, Evan Y., Grivas, Petros, Montgomery, R. Bruce, Gore, John L., Etzioni, Ruth B., Wright, Jonathan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Bladder Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806712/ https://www.ncbi.nlm.nih.gov/pubmed/36601043 http://dx.doi.org/10.1016/j.euros.2022.11.003

Ejemplares similares

Living with Bladder Cancer: Self-reported Changes in Patients’ Functional and Overall Health Status Following Diagnosis
por: Ungerer, Garrett, et al.
Publicado: (2020)

Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study
por: Rezazadeh Kalebasty, Arash, et al.
Publicado: (2022)

Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy
por: Golla, Vishnukamal, et al.
Publicado: (2020)

How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
por: Lee, Hsiang-Ying, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer
por: Maibom, Sophia L., et al.
Publicado: (2021)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice
por: de Ruiter, Ben-Max, et al.
Publicado: (2022)

Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial
por: van Straten, Christine G.J.I., et al.
Publicado: (2023)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)

Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit
por: Tan, Wei Shen, et al.
Publicado: (2021)

Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer
por: Hentschel, Anouk E., et al.
Publicado: (2022)

SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer
por: Lindgren, Maria Skydt, et al.
Publicado: (2021)

Learning Curve Analysis for Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section Scientific Working Group
por: Wijburg, Carl J., et al.
Publicado: (2022)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Intensified and Standardized Digital Communication with Cystectomy Patients as a Potentially Simple and Effective Modality for Early Detection of Postoperative Complications: Results from a Pilot Study
por: Birkhäuser, Frédéric D., et al.
Publicado: (2020)

The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer
por: Muto, Satoru, et al.
Publicado: (2021)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer
por: Schmidt, Bogdana, et al.
Publicado: (2022)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative Data
por: Phull, Manraj, et al.
Publicado: (2023)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Minimum Volume Standards: An Incentive To Perform More Radical Cystectomies?
por: Nuijens, Siberyn T., et al.
Publicado: (2023)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial
por: Yu, Ge, et al.
Publicado: (2023)

The role of switch maintenance therapy in urothelial cancers
por: Yu, Eun-mi, et al.
Publicado: (2023)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer
por: Veeratterapillay, Rajan, et al.
Publicado: (2021)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice
por: Loizzo, Davide, et al.
Publicado: (2022)

Defining Oligometastatic Bladder Cancer: A Systematic Review
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Xpert® bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results
por: D’Elia, Carolina, et al.
Publicado: (2022)

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b1pkjb0k0r5s5d0k3sutu3qenu